Skip to main content

Table 1 Overview of the assays used to evaluate the therapeutic potential of HNE

From: Preclinical evaluation of safety and potential of black hellebore extracts for cancer treatment

Assay

Test principle

Cells

Incubation time (h)

Reference substance

Max. Conc. (μg/ml)

Min. Conc. (μg/ml)

WST-1

Cell viability

HUVEC

24

Paclitaxel

50,000

625

BrdU

Cell proliferation

HUVEC

24

Paclitaxel

50,000

625

Matrigel Angiogenese

Tube Formation 2D

HUVEC

24

Untreated cells

829

13

Spheroid-based Cellular 3D Angiogenesis

Tube Formation 3D

HUVEC

24

Sunitinib

20,000

20

Alamar Blue

Cell viability 2D

Tumor cells

72

Actinomycin-D

10,000

3.33

Soft Agar

Cell viability 3D

Tumor cells

216–288

Actinomycin-D

10,000

3.33

Oris™

Cell migration and invasion

Tumor cells

24–48

SKI-606 (Bosutinib)

1000

600

  1. Seven in vitro assays were used to investigate the mechanism of action and the therapeutic potential of HNE for tumor therapy